Abstract
A multicentre study with an open experimental design was carried out on 118 patients suffering from mild to moderate cognitive decline due to cerebrovascular and degenerative disorders (chronic cerebrovascular disorders, CCVD; multi-infarct dementia, MID; aging brain, AB; dementia of Alzheimer's type, DAT). All patients, after a wash-out period of 3 weeks, were treated with idebenone (45 mg twice daily by oral route) for a period of 6 months. Behavioral and cognitive measures (Sandoz Clinical Assessment of Geriatrics, SCAG; Serial Learning Test) were applied to evaluate the long term therapeutical aspects. The results, analyzed by multivariate analysis of variance and chi2 test, showed a significant improvement of the cognitive profile in all patients, more evident in CCVD and AB groups. No remarkable side-effects were found in all groups of patients, thus confirming good tolerability of idebenone.
References
Sep 1, 1975·Archives of Neurology·V C HachinskiL Symon
May 1, 1989·Archives of Gerontology and Geriatrics·A NagaokaM Kakihana
Jan 1, 1988·The American Journal of Medicine·A D Frank, S A Rosenfeld
Jun 1, 1987·Pharmacology, Biochemistry, and Behavior·M Miyamoto, A Nagaoka
Jul 1, 1968·The British Journal of Psychiatry : the Journal of Mental Science·G BlessedM Roth
Aug 1, 1982·Chemical & Pharmaceutical Bulletin·K OkamotoH Morimoto
Jan 1, 1991·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·M FioravantiW A Stock
Nov 1, 1990·Archives of Gerontology and Geriatrics·I Zs -Nagy
Nov 1, 1990·Archives of Gerontology and Geriatrics·M Murakami, I Zs -Nagy
Nov 1, 1990·Archives of Gerontology and Geriatrics·I Zs -Nagy, R A Floyd
Mar 8, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Jyrki T Kuikka
Citations
May 5, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Yi ChangSu-Jane Wang
May 12, 2009·Neuroscience and Behavioral Physiology·K V Voronkova, M N Meleshkov
Feb 26, 2021·Neuropsychiatric Disease and Treatment·Xudong QianJian Zhang